CIK immunotherapy in refractory hematologic malignancies
Section snippets
Conflict of interest
No conflict of interest to declare.
References (12)
- et al.
In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity
Blood
(2008) - et al.
Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation
Biol. Blood Marrow Transpl.
(2011) - et al.
High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen
Biol. Blood Marrow Transpl.
(2013) - et al.
The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors
Exp. Hematol. Oncol.
(2015) - et al.
Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: a phase I study in patients with relapsed/refractory hematologic malignancies
Leuk. Res.
(2016) - et al.
Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation
Haematologica
(2014)
There are more references available in the full text version of this article.
Cited by (2)
Down-regulation of Treg by interference of enhances the killing effect of CIK on leukemia cell HL-60
2018, European Review for Medical and Pharmacological SciencesAnalytic and dynamic secretory profile of patient-derived cytokine-induced killer cells
2017, Molecular Medicine
© 2016 Elsevier Ltd. All rights reserved.